StemCells, Inc. Initiates Landmark Trial Targeting Communication Highway of the Brain

[Guest guest]

http://www.cnsfoundation.org/site/News2?page=NewsArticle & id=8977 & security=1 &

Study Being Conducted at UCSF Children’s Hospital

StemCells, Inc. (NASDAQ: STEM) announced today that it has commenced patient recruitment for a Phase I clinical trial designed to test the safety and preliminary efficacy of its HuCNS-SC® purified human neural stem cells in Pelizaeus-Merzbacher Disease ( PMD), a neurological disorder that primarily afflicts children. The study is being conducted at the University of California, San Francisco (UCSF) Children’s Hospital, one of the leading medical centers in the United States for neonatology, pediatric neurology and neurosurgery.

PMD results from a defective gene and is characterized by a lack of myelin, a substance that surrounds and insulates nerve cells’ communications fibers. These fibers function much like electrical wires, and without sufficient myelination are unable to properly transmit nerve impulses, leading to the loss of neurological function and eventually death in the most severe forms of PMD. Currently, there are no effective treatment options for patients with PMD.

“Initiation of this first ever human study of neural stem cells in a myelination disorder is a significant milestone, both for our Company and for the stem cell field,†stated Huhn MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. “We are investigating a cell therapy approach to assess the ability of HuCNS-SC cells to produce the myelin needed for nerve cells to communicate with one another and maintain healthy functioning of the central nervous system. It is our hope that this approach will one day lead to a viable treatment option for these afflicted children, and possibly also for patients suffering from other myelination disorders, such as multiple sclerosis, transverse myelitis and certain types of cerebral palsy.â€

The trial is being directed by a team of prominent academic researchers at UCSF. The principal investigator is H. Rowitch, M..D., Ph.D., Chief of Neonatology at UCSF Children’s Hospital, Professor of Pediatrics and Neurological Surgery, member of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, and a Medical Institute investigator. The study co-investigators are Nalin Gupta, M.D., Ph.D., Chief of Pediatric Neurological Surgery, and B.. Strober, M.D., Director of Clinical Services for Child Neurology and Director of the Muscular Dystrophy Clinic at UCSF Children's Hospital.

“We feel very fortunate to be carrying out this landmark study at a world-class medical center in collaboration with a team of highly regarded specialists, all interested in advancing stem cell therapy for neurological disorders,†added Huhn. “The health and well-being of the children participating in this trial is always the primary focus, so we are pleased that such respected clinicians will be providing their significant expertise to these patients.â€

About the PMD Clinical Trial

The Phase I trial is designed to assess the safety and preliminary effectiveness of HuCNS-SC cells as a treatment for PMD. The trial is expected to enroll four patients with connatal PMD, which is the most severe form of the disease. All patients will be transplanted with HuCNS-SC cells, and will be immunosuppressed for nine months. Following transplantation, the patients will be evaluated regularly over a 12-month period in order to monitor and evaluate the safety and tolerability of the HuCNS-SC cells, the surgery, and the immunosuppression. In addition, magnetic resonance imaging (MRI) of the brain post-transplant may enable the measurement of new myelin formation. As the Company intends to follow the effects of this therapy long-term, a separate four-year observational study will be initiated at the conclusion of this trial.

Interested parties may find more information on patient enrollment at http://neonatology.ucsf.edu/nbri/pmd-trial/ or by visiting www.stemcellsinc.com. Additional information about this clinical trial can also be found at www.clinicaltrials.gov.

Love, Gabby. :0)

http://stemcellforautism.blogspot.com/

http://www.facebook.com/gabby911

http://twitter.com/stemcell4autism

"I know of nobody who is purely Autistic or purely neurotypical. Even God had some Autistic moments, which is why the planets all spin." ~ Jerry Newport